Best of ASCO - 2014 Annual Meeting

 

Welcome

Chronic Lymphocytic Leukemia (CLL)

Hematologic Malignancies—Lymphoma and Chronic Lymphocytic Leukemia

2018 ASCO Annual Meeting

Sort by: title abstract no. first author
ABSTRACT TITLEFIRST AUTHORABSTRACT NO.
Association of ATM mutation and unmutated IGHV status with shorter time to first treatment (TTFT): An analysis of multigene mutation profiling and standard prognostic clinical markers in 384 treatment-naive (TN) chronic lymphocytic leukemia (CLL).

Boyu Hu

7523

A phase 2 study to assess the safety and efficacy of umbralisib (TGR-1202) in pts with CLL who are intolerant to prior BTK or PI3Kδ inhibitor therapy.

Anthony R. Mato

7530

A U.S.-based survey: The experiences of 1147 chronic lymphocytic leukemia (CLL) patients (pts).

Brian Koffman

7532

Achievement of complete remission (CR) as an endpoint for patients with chronic lymphocytic leukemia (CLL) treated with ibrutinib.

Paolo Strati

7522

B-cell acute lymphoblastic leukemia (B-ALL) in CLL patients treated with lenalidomide.

Moritz Fuerstenau

7531

Change in tumor lysis syndrome risk after lead-in treatment in a phase 1b/2 study of obinutuzumab, ibrutinib, and venetoclax for chronic lymphocytic leukemia.

Kerry Anne Rogers

7528

Comparison of different phase II studies using sequential combinations of targeted agents for treating chronic lymphocytic leukemia.

Von Tresckow Julia

7513

Depth of response and progression free survival in CLL patients on ibrutinib.

Audrey Sigmund

7514

Differences in biomarker testing and first-line treatment outcome in chronic lymphocytic leukemia patients in the US and EU5.

Chitra Karki

e19512

Distinct immune signatures in chronic lymphocytic leukemia (CLL) and Richter’s syndrome (RS).

Yucai Wang

7524

Durability of response to venetoclax (VEN) in patients with CLL relapsed/refractory to ibrutinib and/or idelalisib.

John C. Byrd

7512

Economic evaluation for the US of venetoclax (VEN) versus ibrutinib (IBR) versus allogeneic hematopoietic stem-cell transplantation (HSCT) for patients (pts) with relapsed or refractory (R/R) chronic lymphocytic leukemia (CLL) with 17p deletion (del 17p).

Nimer Alsaid

7527

Effect of concurrent CYP3A4 interacting medications on ibrutinib outcomes in patients with CLL.

Adam Kittai

e19514

Effect of metformin on survival in CLL and risk stratification using age-adjusted comorbidity indexes: A retrospective analysis of the Roswell Park CLL Database.

Anil Rabindranath Singh

e19511

Efficacy and safety of obinutuzumab in the frontline treatment of CLL patients with comorbidities: The real-world results of Polish Adult Leukemia Group (PALG) retrospective analysis.

Monika Dlugosz-Danecka

e19513

High, durable minimal residual disease negativity (MRD–) with venetoclax + rituximab (VenR) in relapsed/refractory (R/R) CLL: MRD kinetics from phase 3 MURANO study.

Peter Hillmen

7508

Management and outcomes of 222 CLL patients (pts) treated with venetoclax (VEN) in the real world.

Chadi Nabhan

7529

Mitigation of tumor lysis syndrome (TLS) complications with venetoclax (VEN) in CLL.

Matthew Steven Davids

7526

Phase 2 CAPTIVATE results of ibrutinib (ibr) plus venetoclax (ven) in first-line chronic lymphocytic leukemia (CLL).

William G. Wierda

7502

Phase 3 zanubrutinib (BGB-3111) vs bendamustine + rituximab (BR) in patients (pts) with treatment-naïve (TN) chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL).

Peter Hillmen

TPS7581

Prognostic role of beta-2 microglobulin (B2M) in relapsed/refractory (R/R) chronic lymphocytic leukemia (CLL) patients (pts) treated with ibrutinib (ibr).

William G. Wierda

7521

Rapid progression of disease following ibrutinib discontinuation in patients with chronic lymphocytic leukemia.

Paul Joseph Hampel

7525

Role of ofatumumab (OFA) maintenance treatment in relapsed chronic lymphocytic leukemia (CLL): Final analysis of PROLONG study.

Marinus Van Oers

7517

Self-stated and actual practice patterns of general medical oncologists (MO) regarding the use of predictive biomarkers to guide treatment for patients (pts) with chronic lymphocytic leukemia (CLL).

Maricer P. Escalon

e19510

The efficacy of duvelisib monotherapy following disease progression on ofatumumab monotherapy in patients with relapsed/refractory CLL or SLL in the DUO crossover extension study.

Bryone J. Kuss

7533

The GAIA (CLL13) trial: An international intergroup phase III study for frontline therapy in chronic lymphocytic leukemia (CLL).

Von Tresckow Julia

TPS7582